Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gender-specific One-A-Day 50+

This article was originally published in The Tan Sheet

Executive Summary

Bayer Consumer Care introduces a new line of multivitamins formulated to address the leading health concerns and nutritional needs of men and women over the age of 50, the Morristown, N.J.-based firm states July 16. The One-A-Day 50+ Advantage supplements are complete multivitamins, but the women's version contains increased amounts of calcium and vitamin D to support bone strength and breast health, while the men's product supports prostate health with increased lycopene and selenium, Bayer says. Both varieties also contain increased amounts of nutrients to address health concerns shared by men and women, such as vitamins B6, B12, C, E, and folic acid for heart health and ginko for memory and concentration, according to the firm. The products have launched in food, drug and mass market outlets and will retail between $8.29 and $9.29 for a 50-count bottle...

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts